Childhood Kidney Diseases

Korean Society of Pediatric Nephrology (대한소아신장학회)
권호 표지
DOI QR코드

DOI QR Code

Cytomegalovirus Infection in Pediatric Renal Transplant Recipients: A Single Center Experience

  • Kim, Mi Jin (Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine) ;
  • You, Ji Hye (Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine) ;
  • Yeh, Hye Ryun (Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine) ;
  • Lee, Jin A (Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine) ;
  • Lee, Joo Hoon (Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine) ;
  • Park, Young Seo (Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine)
  • Received : 2017.08.15
  • Accepted : 2017.09.21
  • Published : 2017.10.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: To investigate the frequency, presentation, management, and outcome of cytomegalovirus (CMV) infection in pediatric patients who underwent renal transplantation. Methods: We performed a retrospective chart review of 70 patients under the age of 18, who underwent renal transplantation between January 1990 and November 2014. A diagnosis of CMV infection was based on serology, molecular assays, antigenemia assays, and culture. CMV infection was defined as detection of virus and CMV disease was diagnosed when clinical signs and symptoms were present. Results: The number of patients with CMV infection was 18 (25.7% of renal transplant recipients). Twelve were male (66.7%), and the $mean{\pm}standard$ deviation (SD) age at infection was $13.3{\pm}3.9$ years. Median time of infection after renal transplantation was 4 months (range 1.0-31.0 months). Pretransplantation CMV status in the infected group was as follows: donor (D)+/recipient (R)+, 11 (61.1%); D+/R-, 7 (38.9%); D-/R+, 0; and D-/R- 0. Nine patients had CMV disease with fever, leukopenia, thrombocytopenia, or organ involvement such as enteritis, hepatitis, and pneumonitis. The age of disease occurrence was $13.1{\pm}3.9$ years and the median time to disease onset after renal transplantation was 8 months (range 1.0-31.0). Immunosuppressive agents were reduced or discontinued in 14 patients (77.8%), antiviral agents were used in 11 patients (61.1%), and all patients with CMV infection were controlled. Conclusions: A quarter of the patients had CMV infection about 4 months after renal transplantation. CMV infection was successfully treated with reduction of immunosuppressants or with antiviral agents.

Keywords

References

  1. Einollahi B. Cytomegalovirus infection following kidney transplantation: A multicenter study of 3065 cases. International journal of organ transplantation medicine 2012;3:74.
  2. Sagedal S, Nordal KP, Hartmann A, Degre M, Holter E, Foss A, et al. A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients. Transplantation 2000;70:1166-74. https://doi.org/10.1097/00007890-200010270-00007
  3. Razonable RR, Humar A, Practice ASTIDCo. Cytomegalovirus in solid organ transplantation. Am J Transplant 2013;13 Suppl 4:93-106. https://doi.org/10.1111/ajt.12103
  4. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002;34:1094-7. https://doi.org/10.1086/339329
  5. Fijo-Lopez-Viota J, Espinosa-Roman L, Herrero-Hernando C, Sanahuja-Ibanez MJ, Vila-Santandreu A, Praena-Fernandez JM. Cytomegalovirus and paediatric renal transplants: is this a current issue? Nefrologia 2013;33:7-13.
  6. Cordero E, Casasola C, Ecarma R, Danguilan R. Cytomegalovirus disease in kidney transplant recipients: incidence, clinical profile, and risk factors. Transplant Proc 2012;44:694-700. https://doi.org/10.1016/j.transproceed.2011.11.053
  7. Giakoustidis D, Antoniadis A, Fouzas I, Sklavos A, Giakoustidis A, Ouzounidis N, et al. Prevalence and clinical impact of cytomegalovirus infection and disease in renal transplantation: ten years of experience in a single center. Transplantation proceedings: Elsevier, 2012:2715-7.
  8. Carstens J, Andersen HK, Spencer E, Madsen M. Cytomegalovirus infection in renal transplant recipients. Transpl Infect Dis 2006;8:203-12. https://doi.org/10.1111/j.1399-3062.2006.00169.x
  9. Kranz B, Vester U, Wingen AM, Nadalin S, Paul A, Broelsch CE, et al. Acute rejection episodes in pediatric renal transplant recipients with cytomegalovirus infection. Pediatr Transplant 2008;12:474-8. https://doi.org/10.1111/j.1399-3046.2007.00781.x
  10. Camacho-Gonzalez AF, Gutman J, Hymes LC, Leong T, Hilinski JA. 24 weeks of valganciclovir prophylaxis in children after renal transplantation: a 4-year experience. Transplantation 2011;91:245-50. https://doi.org/10.1097/TP.0b013e3181ffffd3
  11. Seo SY, Park SJ, Hwang JY, Hahn SH, Kim SY, Kim HH, et al. The alteration of the positive rate of cytomegalovirus IgG antibody among preschool period children. Korean Journal of Pediatrics 2006;49:51-5. https://doi.org/10.3345/kjp.2006.49.1.51
  12. Ho M. Epidemiology of cytomegalovirus infections. Rev Infect Dis 1990;12 Suppl 7:S701-10. https://doi.org/10.1093/clinids/12.Supplement_7.S701
  13. Bhadauria D, Sharma RK, Kaul A, Prasad N, Gupta A, Gupta A, et al. Cytomegalovirus disease in renal transplant recipients: a single-center experience. Indian J Microbiol 2012;52:510-5. https://doi.org/10.1007/s12088-012-0268-9
  14. Taherimahmoudi M, Ahmadi H, Baradaran N, Montaser-Kouhsari L, Salem S, Mehrsai A, et al. Cytomegalovirus infection and disease following renal transplantation: preliminary report of incidence and potential risk factors. Transplant Proc 2009;41:2841-4. https://doi.org/10.1016/j.transproceed.2009.07.027
  15. Lebranchu Y, Bridoux F, Buchler M, Le Meur Y, Etienne I, Toupance O, et al. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant 2002;2:48-56. https://doi.org/10.1034/j.1600-6143.2002.020109.x
  16. Sia IG, Patel R. New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients. Clin Microbiol Rev 2000;13:83-121, table of contents. https://doi.org/10.1128/CMR.13.1.83-121.2000
  17. Corona-Nakamura AL, Monteon-Ramos FJ, Troyo-Sanroman R, Arias-Merino MJ, Anaya-Prado R. Incidence and predictive factors for cytomegalovirus infection in renal transplant recipients. Transplant Proc 2009;41:2412-5. https://doi.org/10.1016/j.transproceed.2009.05.008
  18. Winston DJ, Busuttil RW. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients. Transplantation 2003;75:229-33. https://doi.org/10.1097/01.TP.0000040601.60276.96
  19. Luan FL, Stuckey LJ, Park JM, Kaul D, Cibrik D, Ojo A. Six-month prophylaxis is cost effective in transplant patients at high risk for cytomegalovirus infection. J Am Soc Nephrol 2009;20:2449-58. https://doi.org/10.1681/ASN.2008111166
  20. Humar A, Lebranchu Y, Vincenti F, Blumberg EA, Punch JD, Limaye AP, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010;10:1228-37. https://doi.org/10.1111/j.1600-6143.2010.03074.x

Cited by

  1. Focal segmental glomerulosclerosis associated with acute cytomegalovirus infection in a renal transplant vol.23, pp.6, 2019, https://doi.org/10.1111/petr.13538